Phaseline

Companies › Neurotech Pharmaceuticals

Neurotech Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 4; Ophthalmology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NT-501/revakinagene taroretcel-lwey
Surgically implanted intraocular device expressing recombinant human ciliary neurotrophic
CTGFPhase 4Macular Telangiectasia Type 2 (MacTel)Jan 2032
NT-501
Cell-based therapy implant manufactured using hollow fiber membrane
–Phase 3Macular Telangiectasia Type 2May 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06397131NT-501Phase 3Macular Telangiectasia Type 2OphthalmologyMay 2028
NCT06971939NT-501/revakinagene taroretcel-lweyPhase 4Macular Telangiectasia Type 2 (MacTel)OphthalmologyJan 2032

Targets

CTGF (1)

Companies with the same targets

–

Companies built like this

Innostellar Biotherapeutics MeiraGTx Ocular UK Tecnoquimicas Price Vision Group NexThera

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.